Ivonescimab
Breast Cancer - Female
Shuangyue Liumonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Breast Cancer - Female cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Ahon Pharmaceutical Co., Ltd. | Phase 3 | BB |
Letrozole Ahon Pharmaceutical Co., Ltd. | Phase 3 | BB |
MELATONIN Virginia Commonwealth University | Phase 3 | B |
Ribociclib H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | CC |
TAMOXIFEN H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Ivonescimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →